Sanofi (NYSE:SNY) announced today that it entered into a definitive merger with therapeutic developer Kadmon (NSDQ:KDMN) for $1.9 billion. The acquisition adds Rezurock (belumosudil), a recently FDA-approved, first-in-class treatment for chronic graft-versus-host disease (cGVHD) for patients over 12 years old who have failed at least two prior lines of systemic therapy, to Sanofi’s transplant portfolio. […]
